



27 March 2026

Subject: Invitation to the 2026 Annual General Meeting of Shareholders

To: Shareholders of T.Man Pharmaceutical Public Company Limited

- Enclosures
1. QR Code for Downloading the Annual Registration Statement/ 2025 Annual Report (Form 56-1 One Report) and the Financial Statements for the Year 2025 in Digital Format
  2. Profiles of the Candidates Nominated for Appointment as Directors
  3. Details of the Auditors and the Remuneration of the Auditors for the Year 2026
  4. Guideline for Attending the Annual General Meeting of Shareholders through electronic media (E-AGM)
  5. Proxy Form (Form A, Form B and Form C)
  6. Profiles of the Independent Directors Proposed to Act as Proxy for the Shareholders and Definition of Independent Directors
  7. The Company's Articles of Association with Respect to the Meeting of Shareholders
  8. Acceptance Form for the 2026 Annual General Meeting of Shareholders via Electronic Media
  9. Privacy Notice for The Annual General Meeting of Shareholders for the Year 2026

The Board of Directors of T.Man Pharmaceutical Public Company Limited (the "Company") No.1/2026, held on 25 February 2026, had resolved to approve the holding of the 2026 Annual General Meeting of Shareholders on Wednesday, 29 April 2026 at 14.00 hrs., through electronic media (E-AGM) only, in accordance with the Emergency Decree on Electronic Meetings B.E. 2563 (2020) and other relevant laws and regulations, at the Company's Meeting Room, No. 69/1 Soi Bang Khun Thian 14, Samae Dam Sub-District, Bang Khun Thian District, Bangkok, to consider the matters pursuant to the following agendas;

**Agenda 1 To consider and acknowledge the operating results of the Company for the year 2025**

Objective and rationale: In compliance with the Public Limited Companies Act, B.E. 2535 (1992) (including the amendments), which requires that the Company's operating results for the past year be reported to the annual general meeting of shareholders, the Company has prepared the report of the Company's operating results for the year 2025 as set out in the Annual Registration Statement/ 2025 Annual Report (Form 56-1 One Report) which can be downloaded via QR Code, the details of which are set out in Enclosure 1 which has been delivered to the shareholders together with this invitation letter.

Board of Directors' opinion: The Board of Directors has considered and deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to acknowledge the operating results of the Company for the year 2025, which contains the summary of the operating results of the Company for the year 2025.

Voting: This agenda is for acknowledgment only and therefore, voting is not required.

**Agenda 2 To consider and approve the audited financial statements of the Company for the year ended 31 December 2025**

Objective and rationale: In compliance with the Public Limited Companies Act, B.E. 2535 (1992) (including the amendments), which requires that the Company prepare and propose the statement of financial position and statement of profit and loss as of the end of the Company's accounting year, which have been audited by the certified public accountant, to the general meeting of shareholders for approval, the Company has prepared the Company's financial statements for the year ended 31 December 2025, which have been audited by the auditor of the Company, reviewed by the Audit Committee and approved by the Board of Directors. The details of the Company's financial statements for the year ended 31 December 2025 shall be as set out in Enclosure 1 which has been delivered to the shareholders together with this invitation letter, with the key information as shown in the following table:

Operating Results	(Unit : Million Baht)			Increase (Decrease) (Percentage)
	Year 2025	Year 2024	Increase (Decrease)	
Total assets	3,783.72	3,455.66	328.06	9.49
Total liabilities	1,666.72	1,685.72	(19.00)	(1.13)
Total shareholders' equity	2,117.00	1,769.93	347.07	19.61
Revenue from sales and services	2,506.12	2,212.65	293.47	13.26
Cost of sales	1,338.24	1,132.67	205.57	18.15
Gross profit	1,167.88	1,079.98	87.90	8.14
Profit for the year	523.07	450.70	72.37	16.06
Basic earnings per share (Baht)	1.31	1.31	0.00	0.00

Board of Directors' opinion: The Board of Directors has considered and deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to consider and approve the Company's financial statements for the year ended 31 December 2025, which have been audited by the certified public accountant, reviewed by the Audit Committee and approved by the Board of Directors.

Voting: This agenda shall be approved by a majority vote of the shareholders attending the meeting and casting their votes, excluding the abstention votes.

Agenda 3 To consider and acknowledge the interim dividend payment, to consider and approve the dividend payment and the allocation of legal reserve

Objective and rationale: In compliance with the Public Limited Companies Act, B.E. 2535 (1992) (including the amendments) and Article 65 and Article 67 of the Company's Articles of Association, the payment of dividend must be approved by the shareholders in a general meeting of shareholders or the Board of Directors may approve an interim dividend payment when it is deemed that the Company has sufficient profit to do so and such dividend payment must be reported to the shareholders in the next meeting. Accordingly, the Company is prohibited from paying dividends out of other monies than the profits and in case of having accumulated loss, the Company is prohibited from paying dividends. In addition, the Company shall reserve not less than 5 percent of the annual net profits, less accumulated loss brought forward (if any) as legal reserve until such legal reserve is not less than 10 percent of the registered capital amount. Furthermore, the Company has a policy to pay dividends amounting to not less than 30 percent of the net profit from the separate financial statements after the deductions of corporate income tax and other required reserves according to the laws and the Company's Articles of Association. Nevertheless, such dividend payment rate may be changed subject to the operating results, financial status, appropriateness, and other factors relating to the operation and management of the Company.

According to the operating results of the Company for the year 2025 from 1 January 2025 to 31 December 2025, the Company has net profit from the separate financial statements of Baht 368,537,429. Nevertheless, the Company has already allocated the net profit as a legal reserve which is equivalent to 10.0 percent of the Company's registered capital. Such amount meets the minimum requirement prescribed under the Public Limited Companies Act, B.E. 2535 (1992) (including the amendments) and the Company's Articles of Association. Therefore, the Company is not required to allocate additional net profit from the Company's operating results for the year 2025 as a legal reserve.

In this regard, after the Board of Directors has considered the operating results of the Company for the year 2025, the Board of Directors deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to approve the payment of the annual dividend from the operating results of the year 2025, paid from the net profit for the year 2025 at the rate of Baht 0.56 per share for the Company's total issued and paid-up ordinary shares of 400,003,600 shares, totaling Baht 224,002,016. The dividend payment represents 60.78 percent of the net profit from the separate financial statements after the deductions of corporate income

tax and other required reserves according to the laws and the Company's Articles of Association, which is in accordance with the Company's dividend payment policy. The payment details are as follows:

(1) Interim dividend payment for the year 2025

Regarding the meeting of the Board of Directors No. 2/2025 on 11 August 2025, it was resolved to approve the interim dividend payment at the rate of Baht 0.24 per share for 400,003,600 of the Company's issued and paid-up ordinary shares, totaling Baht 96,000,864. The payment was made on 9 September 2025 and was paid from an interim net profit for the year 2025, which represents 26.05 percent of the net profit from the separate financial statements after the deductions for corporate income tax and other required reserves according to the laws and the Company's Articles of Association.

(2) Annual dividend payment for the year 2025 in addition to the interim dividend

As the Company has already paid the interim dividend for the year 2025 as stated in item (1), the Board of Directors therefore deems it appropriate to propose payment of an additional dividend at the rate of Baht 0.32 per share for 400,003,600 of the Company's issued and paid-up ordinary shares, totaling Baht 128,001,152. Such dividend will be paid from the Company's unallocated net profits for the year 2025, which is the net profit of the business that has paid corporate income tax at the rate of 20 percent. Individual shareholders are entitled to tax credits in calculating dividend tax according to Section 47 bis of the Revenue Code. In this regard, the dividend payment represents 34.73 percent of the net profit from the separate financial statements after the deductions of corporate income tax and other required reserves according to laws and the Company's Articles of Association.

The details of the dividend payout ratio for this year compared to the previous year are as shown in the following table.

Item	Year 2025 (Proposed year)	Year 2024
1. Net profits (Baht)	368,537,429	1,171,141,744
2. Legal reserve (Baht)	-	23,800,270
3. Net profit after legal reserve deduction (Baht)	368,537,429	1,147,341,474
4. Retained earnings at the beginning of the period (Baht)	222,958,109	415,150,528
5. Number of shares (Shares) as of December 31	400,003,600	400,003,600
6. Weighted average number of shares (Shares) as of December 31	400,003,600	343,406,059
7. Earnings per share (Baht/share)	0.92	3.41
8. Retained earnings at the beginning of the period per share (Baht/share)	0.56	1.21

Item	Year 2025 (Proposed year)	Year 2024
9. Dividend payment for the year from the Company's net profits	Baht 0.56 per issued and paid-up ordinary share for 400,003,600 shares	Baht 2.9135 <sup>(1)</sup> per weighted average issued and paid-up ordinary share
	Totalling Baht 224,002,016	Totalling Baht 1,000,501,876
- Interim dividend payment (paid from the net profits of the year)	Baht 0.24 per issued and paid-up ordinary share for 400,003,600 shares	Baht 0.5218 <sup>(1)</sup> per weighted average issued and paid-up ordinary share
		Baht 0.5454 <sup>(2)</sup> per issued and paid-up ordinary share for 328,573,600 shares
	Totalling Baht 96,000,864	Totalling Baht 179,204,041 <sup>(1)</sup>
- Interim dividend payment No.2 (paid from net profits of the year)	-	Baht 2.1587 <sup>(1)</sup> per weighted average issued and paid-up ordinary share
		Baht 2.2561 <sup>(2)</sup> per issued and paid-up ordinary share for 328,573,600 shares
		Totalling Baht 741,297,115 <sup>(1)</sup>
- Interim dividend payment No.2 (paid from retained earnings)	-	Baht 1.2635 <sup>(2)</sup> per issued and paid-up ordinary share for 328,573,600 shares
		Totalling Baht 415,150,528 <sup>(1)</sup>
- Annual dividend payment in addition to the interim dividend	Baht 0.32 per issued and paid-up ordinary share for 400,003,600 shares	Baht 0.2330 <sup>(1)</sup> per weighted average issued and paid-up ordinary share
		Baht 0.20 <sup>(2)</sup> per issued and paid-up ordinary share for 400,003,600 shares
		Totalling Baht 80,000,720
	Totalling Baht 128,001,152	Totalling Baht 80,000,720
10. Annual dividend payout ratio to net profit after legal reserve deduction (percent)	60.78	87.20

Remarks: <sup>(1)</sup> Figures have been rounded. <sup>(2)</sup> Actual dividend per share rate.

Board of Directors' opinion: The Board of Directors has considered various factors, including relevant laws and policies, and has resolved to propose to the 2026 Annual General Meeting of Shareholders to omit the allocation of net profit as a legal reserve, to consider and acknowledge the interim dividend payment, and to consider and approve the dividend payment, with the details as proposed.

In this regard, the Company shall pay the dividend to the shareholders whose names appear on the record date for determining the shareholders entitled to receive the dividend which is on 11 May 2026 (Record Date), whereby the dividend payment is scheduled for 26 May 2026. Nevertheless, the entitlement to receive the dividend is uncertain, as it is subject to the approval of the 2026 Annual General Meeting of Shareholders.

Voting: This agenda shall be approved by a majority vote of the shareholders attending the meeting and casting their votes, excluding the abstention votes.

**Agenda 4 To consider and approve the appointment of directors to replace those who retired by rotation**

Objective and rationale: In compliance with the Public Limited Companies Act, B.E. 2535 (1992) (including the amendments) and Article 27 of the Company's Articles of Association, in every annual general meeting of shareholders, one-third of directors must retire from office by rotation. In the case that the number of directors cannot be divided into 3 proportions, the number of directors closest to one-third shall retire. The directors retiring from the office by rotation shall be eligible for re-appointment. For the 2026 Annual General Meeting of Shareholders, there are 3 directors who shall retire from office as follows:

1. Dr. Sunee Sornchaitanasuk Director/Independent Director
2. Mr. Sakchai Peechatat Director/Independent Director
3. Ms. Orapan Thanachotipan Director

The Company has provided the shareholders with the opportunity to nominate candidates to be considered for appointment as the Company's director from 12 November 2025 to 31 January 2026. However, no shareholder has nominated any candidates for appointment as the Company's director.

In this regard, the Nomination and Remuneration Committee has considered the qualifications of the directors retiring by rotation for the 2026 Annual General Meeting of Shareholders and is of the opinion that the 3 retiring directors possess appropriate and comprehensive qualifications. They are regarded as experts with knowledge, abilities and experience in various fields that are aligned with the Company's business operation, including having performed their duties as directors and sub-committees well during their office terms. Therefore, the Nomination and Remuneration Committee deemed it appropriate to propose the reappointment

of such 3 directors mentioned above as the directors and/or independent director of the Company for another term to the Board of Directors.

In consideration of the 3 persons who have been nominated as the Company's directors, the Nomination and Remuneration Committee has taken into account the nomination guidelines and processes by considering whether all 3 persons are qualified and do not possess prohibited characteristics according to the Public Limited Companies Act, B.E. 2535 (1992) (including the amendments), the Securities and Exchanges Act, B.E. 2535 (1992) (including the amendments) and the related notifications. Furthermore, those who shall hold the office as an independent director possess the qualification of an independent director pursuant to the definition of an independent director of the Company, details of which are as stipulated by the regulations of the Office of the Securities and Exchange Commission and the Stock Exchange of Thailand and are capable of giving their opinions independently and in compliance with the relevant rules and regulations. The details and profiles of such 3 candidates are as set out in Enclosure 2 which has been delivered to the shareholders together with this invitation letter.

Board of Directors' opinion: The Board of Directors has considered, in accordance with the screening process pursuant to the Company's nomination policy, and is of the opinion that the persons who have been nominated this time have passed the consideration pursuant to the processes stipulated by the Company and possess the qualifications in compliance with the relevant rules and regulations and are appropriate for the Company's business operation. In addition, for the persons nominated as the independent director, the Board of Directors has considered and is of the opinion that the persons who are nominated as the independent director possess the qualifications of an independent director pursuant to the rules and regulations relevant to the independent directors and qualify as an independent director pursuant to the definition of an independent director of the Company, details of which are as stipulated by the regulations of the Office of the Securities and Exchange Commission; as well as being able to provide independent opinion. Therefore, the Board of Directors deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to consider and approve the re-appointment of the 3 candidates, whose names appear as follows, to hold the office as the Company's director and/or independent director for another term:

- |                              |                               |
|------------------------------|-------------------------------|
| 1. Dr. Sunee Sornchaitanasuk | Director/Independent Director |
| 2. Mr. Sakchai Peechapat     | Director/Independent Director |
| 3. Ms. Orapan Thanachotipan  | Director                      |

Voting: This agenda shall be approved by a majority vote of the shareholders attending the meeting and casting their votes, excluding the abstention votes. (For the appointment of the directors to replace those who retired by rotation, the Company shall proceed with the voting of each candidate individually.)

Agenda 5 To consider and approve the remuneration for the directors and the sub-committees of the Company for the year 2026

Objective and rationale: In compliance with the Public Limited Companies Act, B.E. 2535 (1992) (including the amendments) and Article 44 of the Company's Articles of Association, the directors are eligible to receive remuneration from the Company in the form of rewards, meeting allowances, gratuities, bonuses or any other forms of benefits as determined by the general meeting of shareholders. The remuneration may be fixed or determined in principle and may be prescribed from time to time or may remain effective until the general meeting of shareholders has resolved to change otherwise. The foregoing shall not affect the rights of the employees of the Company who are also appointed as the Company's directors to receive remuneration and benefits as the employee of the Company.

In this regard, the Nomination and Remuneration Committee has considered the appropriateness of the remuneration for the Board of Directors and the sub-committees, carefully taking into account the appropriateness in various aspects, namely, the Company's operating performance, the business size and the extent of responsibilities and obligations of the Board of Directors and the sub-committees and comparing the remuneration rate with that of the other companies of similar size and in the same industrial field of business as the Company. Therefore, the Board of Directors deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to consider and approve the monthly remuneration and meeting allowance for the Board of Directors and the sub-committees for the year 2026 pursuant to the following details:

No.	Board Committee	Position	Meeting Allowance (Baht/Time)	Bonus
1.	Board of Directors	Chairman	80,000	For non-executive directors, the rate is 0.5 percent of the declared dividend amount. When combined with meeting allowances, the total should not exceed Baht 5,000,000 per year. The Board of Directors will consider and determine the appropriate amount and
		Non - Executive Director	35,000	
		Executive Director	5,000	
2.	Audit Committee	Chairman of the Audit Committee	50,000	
		Member of the Audit Committee	30,000	
3.	Nomination and Remuneration Committee	Chairman of the Nomination and Remuneration Committee	15,000	
		Member of the Nomination and Remuneration Committee	10,000	

No.	Board Committee	Position	Meeting Allowance (Baht/Time)	Bonus
4.	Risk Management Committee	Chairman of the Risk Management Committee	15,000	consider the payment of such remuneration.
		Member of the Risk Management Committee	10,000	
5.	Corporate Governance and Sustainability Committee	Chairman of the Corporate Governance and Sustainability Committee	15,000	
		Member of the Corporate Governance and Sustainability Committee	10,000	
6.	Other Committees	Chairman of the Committee	15,000	
		Member of the Committee	10,000	

Board of Directors' opinion: The Board of Directors has considered and deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to consider and approve the remuneration of the directors for the year 2026 as proposed, whereby the remuneration of the Board of Directors and the sub-committees shall be divided into 2 types: (1) meeting allowance and (2) bonus, without any other remuneration or benefits, where the total remuneration of the board committees under (1) and (2) shall be at the amount not exceeding Baht 5,000,000. The Board of Directors is authorized to determine the appropriate amount of the remuneration and consider the payment of such remuneration. In this regard, the proposed remuneration is set at the same rate as the remuneration of the Board of Directors and sub-committees for the year 2025. The proposal includes the determination of remuneration for the Corporate Governance and Sustainability Committee, a newly established sub-committee of the Board of Directors, and the establishment of a remuneration framework for any additional sub-committees that may be established by the Board during the year, to ensure continuity and efficiency in the Company's corporate governance. Nevertheless, this proposed stipulation of the remuneration of the directors shall remain effective until the general meeting of shareholders has resolved to change otherwise.

Voting: This agenda shall be approved by not less than two-thirds of the total votes of the shareholders who attended the meeting.

**Agenda 6 To consider and approve the appointment of auditors and the determination of remuneration of the auditors for the year 2026**

Objective and rationale: In compliance with the Public Limited Companies Act, B.E. 2535 (1992) (including the amendments) and Article 62 of the Company's Articles of Association, every annual general meeting of shareholders shall consider and appoint an auditor of the Company and determine the remuneration of the auditor for the year. In addition, the Notification of the Securities and Exchange Commission stipulates that the company listed on the Stock Exchange of Thailand shall ensure that there is a rotation of auditors in the case where the existing auditor has performed their duties of auditing, reviewing and rendering opinions on the Company's financial statements for 7 accounting years, whether consecutively or not. In this regard, the Company shall be able to appoint such auditor as the auditor of the Company after the expiration of at least 5 consecutive accounting years.

In this regard, the auditors and the remuneration of the auditor for the year 2026, which shall be proposed to the 2026 Annual General Meeting of Shareholders for consideration and approval, have been considered and selected by the Audit Committee and the Board of Directors which deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to consider and approve the appointment of the auditors from KPMG Phoomchai Audit Company Limited to be the Company's auditors for the year 2026, due to their experience, expertise along with other relevant qualifications. Furthermore, they have received approval from the Office of the Securities and Exchange Commission, have no relationship and/or conflict of interest with the Company and/or executives and/or major shareholders or individuals related to the aforementioned persons and possess sufficient independence to audit and provide an opinion towards the Company's financial statements. Therefore, the Board of Directors deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to consider and approve the appointment of the auditors for the year 2026 pursuant to the following details:

No.	Name	Certified Public Accountant No.	History of auditing the Company
1.	Mr. Ekkasit Chuthamsatid	4195 and/or	Has signed the Company's financial statements for the fiscal year 2023, 2024 and 2025, covering a total period of 3 years.

No.	Name	Certified Public Accountant No.	History of auditing the Company
2.	Miss Nawarat Nitikeatipong	7789 and/or	-
3.	Miss Vilaivan Pholprasert	8420 and/or	-
4.	Miss Nadsasin Wattanapaisal	10767 and/or	-
5.	Miss Pannida Suksawat	11722	-

In addition, the determination of the remuneration of the auditor for the year 2026 has been considered to be in the amount of Baht 1,600,000 for the year ended 31 December 2026 and such remuneration of the auditor was considered appropriate compared to the scope of audit. In this regard, such auditor fee is exclusive of other fees (Non-Audit Fee) which the Company shall pay on an actual basis.

Therefore, the Board of Directors deemed it appropriate to propose such matter to the 2026 Annual General Meeting of Shareholders for consideration and approval. The details of the auditors and the remuneration of the auditor for the year 2026 are as set out in Enclosure 3 which has been delivered to the shareholders together with this invitation letter. The key information can be summarized as follows:

	Year 2026 (Baht) (Proposed Year)	Year 2025 (Baht)	Increase (Decrease) Percentage
Audit fee	1,600,000	1,600,000	0.00
Non-Audit fee	Actual Basis	-	-

Board of Directors' opinion: The Board of Directors has considered and deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to consider and approve the appointment of auditors from KPMG Phoomchai Audit Company Limited, namely: Mr. Ekkasit Chuthamsatid, certified public accountant registration No. 4195 and/or Miss Nawarat Nitikeatipong, certified public accountant registration No. 7789 and/or Miss Vilaivan Pholprasert, certified public accountant registration No. 8420 and/or Miss Nadsasin Wattanapaisal, certified public accountant registration No. 10767 and/or Miss Pannida Suksawat, certified public accountant registration No. 11722 as the auditors of the Company for the year 2026, whereby any of the above auditors shall audit and provide opinion towards the Company's financial statements. In the event that the abovementioned auditors are unable to perform their duties, the Company can appoint another certified public accountant from KPMG Phoomchai Audit Company Limited to perform the duties on their behalf. In addition, the Board of Directors has considered and deemed it appropriate to propose to the 2026 Annual

General Meeting of Shareholders to determine the auditor fee for the year 2026 in the amount of Baht 1,600,000 which is exclusive of the other related service fees, details of which are as provided above.

In addition, the Company's subsidiaries have engaged the same auditing company as the Company for the year 2026, KPMG Phoomchai Audit Company Limited, whereby the auditors nominated above have no relationship and/or conflict of interest with the Company and/or subsidiaries and/or executives and/or major shareholders or individuals related to the aforementioned persons in any manner that may affect the independence in their performance of duties.

Voting: This agenda shall be approved by a majority vote of the shareholders attending the meeting and casting their votes, excluding the abstention votes.

#### Agenda 7 Other matters (if any)

The Company has determined the record date to determine the names of the shareholders who are entitled to attend the 2026 Annual General Meeting of Shareholders to be on 20 March 2026 (Record date).

From 12 November 2025 to 31 January 2026, the Company has given the shareholders the opportunity to propose agendas for the 2026 Annual General Meeting of Shareholders through the Company's website. However, no shareholder has proposed any agendas for the 2026 Annual General Meeting of Shareholders.

In this regard, shareholders and/or proxy who wish to attend the Meeting can register and verify their identity in advance from 6 April 2026 to 24 April 2026, by preparing and submitting the acceptance form for the 2026 Annual General Meeting of Shareholders via electronic media as set out in Enclosure 8, and the Proxy Form (only in case of proxy appointment), as set out in Enclosure 5, together with supporting documents shown in Enclosure 4, to the Company via email at [ir@tmanpharma.co.th](mailto:ir@tmanpharma.co.th) or through E-Request using the QR code shown in Enclosure 4.

Should any shareholder wish to appoint a proxy to attend the meeting and cast their vote at this meeting, please fill in the details and sign one of the Proxy Forms as set out in Enclosure 5 or the shareholder may download the Proxy Form from the Company's website at <https://investor.tmanpharmaceutical.com/th/downloads/shareholders-meeting>. For the shareholder who wishes to appoint the Company's independent director, whose name appears in Enclosure 6, to attend the meeting on their behalf as proxy, please fill in the details and sign one of the Proxy Forms as set out in Enclosure 5 and deliver the same, along with the supporting documents as shown in Enclosure 4, to the Company via the aforementioned channel and deliver the original copy of such documents to the Company.

With regard to ensuring the convenience and efficiency of the registration process for the meeting, shareholders or proxy holders are kindly requested to deliver original copies of the aforementioned documents to the Company at the address below prior to the meeting by post within **24 April 2026**.



# บริษัท ที.แมน ฟาร์มาซูติคอล จำกัด (มหาชน)

T.MAN PHARMACEUTICAL PUBLIC COMPANY LIMITED [www.tmanpharmaceutical.com](http://www.tmanpharmaceutical.com)

To: Company Secretary

T.Man Pharmaceutical Public Company Limited

No. 69/1 14 Bang Khun Thian Alley, Samae Dam Sub-District, Bang Khun Thian District,

Bangkok, 10150

(For the 2026 Annual General Meeting of Shareholders)

Subsequent to the verification of the list and the accuracy of the documents of shareholders or proxy holders wishing to attend the meeting, the Company and/or OJ International Co., Ltd., which is the service provider for the meeting control system and has been assessed for its meeting control system compliance with the Standards for Maintaining Information Security for Meeting Control Systems B.E. 2563 (2020) under the self-assessment scheme by the Electronic Transactions Development Agency (ETDA), will send the link for accessing the meeting via electronic media (E-AGM) to shareholders or proxy holders along with the manual for using the electronic annual general meeting system (E-AGM), via the email address provided under the conditions and within the time period as shown in Enclosure 4.

In this regard, shareholders and/or proxy holders who wish to attend the Meeting are kindly requested to study the guidelines for attending the annual general meeting of shareholders through electronic media (E-AGM) pursuant to the details as set out in Enclosure 4. On the meeting day, the registration to verify the attendance through Zoom Cloud Meeting shall begin from 12.00 hrs. onwards and the Company shall convene the meeting in accordance with the Company's Articles of Association with respect to the meeting of shareholders as set out in Enclosure 7.

The Company has prepared the Annual Registration Statement/ 2025 Annual Report (Form 56-1 One Report) only in electronic format in order to reduce the environmental impact on natural resource depletion and climate crisis from the business operation, as part of its commitment to the goal of conducting business responsibly (Responsible Business).

Moreover, the Company has published the invitation letter to the 2026 Annual General Meeting of Shareholders, together with the enclosures, on the Company's website: <https://investor.tmanpharmaceutical.com/en/downloads/shareholders-meeting>, whereby the Company will convene the meeting via electronic media (E-AGM) only. In this regard, all shareholders are cordially invited to attend the 2026 Annual General Meeting of Shareholders according to the date, time and format mentioned above.

Best regards,

(Mr. Prapon Thanachotipan)

Chief Executive Officer

Authorized person to disclose information of

T.Man Pharmaceutical Public Company Limited

**COLLABORATION  
FOR INNOVATION**

ร่วมสร้างสรรค์นวัตกรรมสุขภาพไปด้วยกัน